Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | AGL | P35573 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | LCT | P09848 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24782349 | 0.83 | SLC6A9 (0.35) | SLC6A9TDP1SPHK2SPHK1POLB | |
| SCHEMBL24926332 | 0.82 | GBA1 (0.38) | GBA1TDP1 | |
| SCHEMBL18199654 | 0.82 | GBA1 (0.38) | GBA1TDP1 | |
| SCHEMBL15471354 | 0.82 | GBA1 (0.38) | GBA1TDP1 | |
| SCHEMBL24926315 | 0.80 | SLC6A9 (0.34) | SLC6A9 | |
| SCHEMBL22541496 | 0.80 | SLC6A9 (0.34) | SLC6A9 | |
| SCHEMBL24926283 | 0.78 | GBA2 (0.41) | AGLGAAGBA1MGAMSI | |
| SCHEMBL13297123 | 0.78 | HTT (0.34) | HTTAGLGBA1SPHK2SPHK1 | |
| SCHEMBL24926618 | 0.77 | S1PR1 (0.44) | GAAGBA1SPHK2SPHK1 | |
| SCHEMBL24926322 | 0.77 | HSD11B1 (0.40) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | HTT 2021/4885SLC6A9 622/4885AGL 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.